VERA

Vera Therapeutics' stock has increased by 44.82% in the past six months but has decreased by 28.5% since the start of the year. Key events include the FDA's Priority Review for atacicept, Q1 2026 financial results showing a wider net loss due to increased spending, Q4 2025 financial results reporting a net loss, an analyst rating downgrade due to competition, insider stock sales, and equity awards to new employees.